Combination therapy for glioblastoma with a personalized vaccine
Treatments studied
Part of Cancer clinical trials.
This study tests a combination treatment for glioblastoma, a type of brain cancer. It includes a personalized vaccine made from your tumor, along with chemotherapy and an immunotherapy drug (anti-PD-1). The goal is to see if this combination helps people with this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 71 years old.
- You must have been diagnosed with glioblastoma and have a tumor sample sent for testing.
- You must be in generally good health (able to do daily activities).
- You must not have had prior treatment with anti-PD-1/PD-L1 drugs.
- You must not have other serious medical conditions such as an active infection, autoimmune disease, or recent steroid use.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial tests a treatment that combines a custom-made vaccine from your tumor, chemotherapy, and an immunotherapy drug. It is designed for people with triple negative breast cancer that has spread or can't be removed and no longer responds to the standard first treatment.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
This trial tests a personalized vaccine (made from your own immune cells and tumor 'neoantigens') combined with the chemotherapy drug temozolomide for people with newly diagnosed glioblastoma. The goal is to see if adding the vaccine helps the immune system better fight the tumor.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
This trial tests a new vaccine (UCPVax) with or without pembrolizumab (an immunotherapy) given after standard radiation and chemotherapy for people with a specific type of glioblastoma (MGMT unmethylated). The goal is to see if adding these treatments can help prevent the cancer from coming back.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.